HQH
THQ
HQL
THW

Chris LaVictoire Mahai

Known title: DirectorCIK: 0001335892

Chris LaVictoire Mahai's purchase track record

Chris LaVictoire Mahai has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
7/16/2026THW$11K-8.3%pending
7/16/2026THQ$11K-2.8%pending
7/16/2026HQL$10K-12.5%pending
7/16/2026HQH$11K-7.3%pending

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

HQH Healthcare Fund Draws Attention for High Dividend Yield. Recent articles highlight HQH's dividend yield, which stands at 10.07% according to current data. One piece notes a cash yield above 9%, while another describes the fund as offering over 10% yield. These reports focus on the income potential of this healthcare-focused vehicle rather than recent operational changes.

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 26, 2026

HQL Listed Among Top CEFs for September 2026 Yield. abrdn Life Sciences Investors (HQL) was included in a recent list of the ten best closed-end funds for September 2026, which highlights an average yield of 10%. This inclusion suggests the fund is being noted for its income potential within the broader CEF market. The stock is currently trading near its support level, reflecting a mixed technical picture alongside this fundamental recognition.

Transaction History

HQH▲ Buy$11K
THQ▲ Buy$11K
HQL▲ Buy$10K
THW▲ Buy$11K

We use analytics to understand how market-wall is used. No personal data is sold.